GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (NAS:RARE) » Definitions » Price-to-Free-Cash-Flow

RARE (Ultragenyx Pharmaceutical) Price-to-Free-Cash-Flow : N/A (As of Dec. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ultragenyx Pharmaceutical Price-to-Free-Cash-Flow?

As of today (2024-12-14), Ultragenyx Pharmaceutical's share price is $45.78. Ultragenyx Pharmaceutical's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-5.13. Hence, Ultragenyx Pharmaceutical's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Ultragenyx Pharmaceutical's Price-to-Free-Cash-Flow or its related term are showing as below:

RARE's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 35.18
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Ultragenyx Pharmaceutical's Free Cash Flow per Share for the three months ended in Sep. 2024 was $-0.72. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-5.13.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -34.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -6.10% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -16.60% per year.

During the past 13 years, Ultragenyx Pharmaceutical's highest 3-Year average Free Cash Flow per Share Growth Rate was 21.80% per year. The lowest was -80.60% per year. And the median was -30.00% per year.


Ultragenyx Pharmaceutical Price-to-Free-Cash-Flow Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Price-to-Free-Cash-Flow Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ultragenyx Pharmaceutical Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ultragenyx Pharmaceutical's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Price-to-Free-Cash-Flow falls into.



Ultragenyx Pharmaceutical Price-to-Free-Cash-Flow Calculation

Ultragenyx Pharmaceutical's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=45.78/-5.132
=N/A

Ultragenyx Pharmaceutical's Share Price of today is $45.78.
Ultragenyx Pharmaceutical's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.13.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Ultragenyx Pharmaceutical  (NAS:RARE) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Ultragenyx Pharmaceutical Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Executives
Howard Horn officer: Chief Financial Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Theodore Alan Huizenga officer: Controller and PAO C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Emil D Kakkis director, 10 percent owner, officer: President & CEO C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Sanders Corazon (corsee) D. director C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Karah Herdman Parschauer officer: EVP and General Counsel 60 LEVERONI COURT, NOVATO CA 94949
Eric Crombez officer: EVP and Chief Medical Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Thomas Richard Kassberg officer: CBO & Senior Vice President C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Erik Harris officer: EVP & Chief Commercial Officer 60 LEVERONI COURT, NOVATO CA 94949
John Richard Pinion officer: See Remarks C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Dennis Karl Huang officer: SVP and Chief Tech Ops Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Camille L Bedrosian officer: EVP and Chief Medical Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Mardi Dier officer: CFO & Executive Vice President C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Amrit Ray director 60 LEVERONI COURT, NOVATO CA 94949
William Aliski director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949